WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018053709) THE NOVEL MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH 1 (PD-1)
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2018/053709    International Application No.:    PCT/CN2016/099576
Publication Date: 29.03.2018 International Filing Date: 21.09.2016
IPC:
C07K 16/28 (2006.01), C12N 15/13 (2006.01), C12N 15/63 (2006.01), C12N 5/10 (2006.01), C12N 5/20 (2006.01), A61K 39/395 (2006.01), A61P 35/00 (2006.01)
Applicants: WUXI BIOLOGICS (SHANGHAI) CO., LTD. [CN/CN]; Shanghai Free Trade Zone, FuTe Zhong Road 288 Shanghai 200131 (CN)
Inventors: ZHENG, Yong; (CN).
LI, Jing; (US).
GOLOLOBOV, Gennady; (US).
ZHANG, Xinhua; (CN).
YANG, Baotian; (CN).
TANG, Zhewei; (CN).
LI, Dong; (CN).
XU, Jianqing; (CN).
WANG, Zhuozhi; (US)
Agent: F & S INTELLECTUAL PROPERTY LTD.; Room 1402, Tower B Horizon International Tower No.6 Zhichun Road Haidian District, Beijing 100191 (CN).
WU, Li; (CN).
ZOU, Yijiao; (CN)
Priority Data:
Title (EN) THE NOVEL MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH 1 (PD-1)
(FR) NOUVEAUX ANTICORPS MONOCLONAUX DIRIGÉS CONTRE LA MORT PROGRAMMÉE 1 (PD -1)
Abstract: front page image
(EN)The present invention provides PD-1 monoclonal antibodies, particularly human monoclonal antibodies of PD-1, which specifically bind to PD-1 with high affinity and comprise a heavy chain and a light chain. The present invention further provides nucleic acid sequence encoding the antibodies of the invention, cloning or expression vectors, host cells and methods for expressing or isolating the antibodies. Immunoconjugates, therapeutic compositions comprising the antibodies of the invention are also provided. The invention also provides methods for treating various cancers with anti-PD-1 antibodies.
(FR)La présente invention concerne des anticorps monoclonaux PD -1, en particulier des anticorps monoclonaux humains de PD -1, qui se lient spécifiquement à PD -1 avec une affinité élevée et comprennent une chaîne lourde et une chaîne légère. La présente invention concerne en outre une séquence d'acides nucléiques codant pour les anticorps de l'invention, des vecteurs de clonage ou d'expression, des cellules hôtes et des procédés pour exprimer ou isoler les anticorps. L'invention concerne en outre des immunoconjugués, des compositions thérapeutiques comprenant les anticorps de l'invention. L'invention concerne également des procédés de traitement de divers cancers avec des anticorps anti-PD -1.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)